Navigation Links
Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
Date:12/6/2010

hieved a partial response with a median response duration of 9 months.  An additional 6 patients receiving the combination (40%) achieved stable disease.  The combination was well tolerated with no unexpected safety events.

The investigators concluded that perifosine in combination with sorafenib has significant anti-lymphoma activity in relapsed/refractory HL, and that perifosine as a single agent induced prolonged responses in high-risk, heavily pretreated CLL patients.

Abstract # 1842:  "Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)"Study Background:  In this Phase 2 study, 12 patients with advanced CLL began treatment with single agent perifosine at 50 mg BID. Patients on study were heavily pre-treated having had a median of 4 prior lines of therapy with 75% of patients classified as Rai stage IV.

Results:  1 patient achieved a partial response (5 months on treatment) and 5 additional patients achieved stable disease (median duration of 4.25 months), for an overall 50% clinical benefit rate (PR + SD).  Perifosine was well tolerated with minimal dose modifications.

Abstract #3064: "Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)"Additionally, the final dataset from the Phase 1 study of perifosine + lenalidomide (Revlimid®) + dexamethasone was also presented during the ASH meeting.  The final data showed a 73% objective response rate (minimal response or better) with a 50% PR or better, a median Progression-Free Survival of 10.8 months, and a median duration for Overall Survival of 30.6 months.  The myeloma investigators concluded that perifosine in combination with lenalidomide + dexamethasone was well tolerated even at the highest doses used, and demonstrated encouraging clini
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
2. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
3. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
4. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
5. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... it is now offering the MonaLisa Touch® , an innovative vaginal health ... MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition that ...
(Date:9/1/2015)... ... , ... The Jerry Segal Classic to benefit the patients of Magee Rehabilitation ... in Lafayette Hill, PA. Over the past 26 years, the Classic, organized by the ... designed to support patients and their families during their time at Magee Rehabilitation Hospital. ...
(Date:9/1/2015)... Francisco, Calif. (PRWEB) , ... September 01, 2015 ... ... to corporations, law firms and government entities, announced today that it has hired ... Senior Discovery Consultant. In this capacity, Sanderson will be responsible for establishing ...
(Date:9/1/2015)... New York, New York (PRWEB) , ... September 01, 2015 , ... ... of Zecurion Zlock Mac , its groundbreaking new version of endpoint DLP developed ... testing of Zlock Mac, in which more than 100 IT and information security professionals ...
(Date:9/1/2015)... D.C. (PRWEB) , ... September 01, 2015 , ... Two ... better cross cultural relations through food and dining. , Recently named “the next ... and Luigi Diotaiuti are known for telling the whole story behind food and reclaiming ...
Breaking Medicine News(10 mins):Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:Zecurion Announces Endpoint Security for Mac 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4
... National Institute of Biomedical Imaging and Bioengineering (NIBIB) Laboratory ... technique that allows researchers to visualize fine details of ... insight into how cells are organized and how they ... online this week in Nature Methods . ...
... type 2 diabetes are not consuming sufficiently healthy diets and ... a new study by researchers at Wake Forest University School ... the August issue of the Journal of the American ... diabetes, especially type 2 diabetes, is being able to manage ...
... , , ATLANTA, ... GTIV ), a leading provider of comprehensive home health services, ... Company,s Board of Directors: Philip R. Lochner, Jr., Sheldon M. ... Gentiva has re-established an independent majority on its Board and ...
... PHILADELPHIA, Sept. 3 ERT (Nasdaq: ERES ... thorough QT clinical Trial (TET). ERT provides full TET ... provision of ECG equipment to ECG analysis, data processing, management, ... Cardiac safety concerns continue to be the primary ...
... - NUCRYST Pharmaceuticals, a developer and manufacturer of ... Wound Management division of Smith Nephew ... Flex3 and Acticoat(TM) Flex7. The Flex range is ... dressings with NUCRYST,s proprietary SILCRYST(TM) nanocrystalline silver coatings. ...
... Online ... named to the prestigious 2009 Inc. magazine 500/5000 list of the country,s fastest growing ... ... has been named to the prestigious 2009 Inc. magazine 500/5000 list of the country,s ...
Cached Medicine News:Health News:NIBIB scientists increase imaging efficiency in cell structure studies 2Health News:People with type 2 diabetes not meeting important nutritional recommendations 2Health News:People with type 2 diabetes not meeting important nutritional recommendations 3Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 2Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 3Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 4Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 5Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 6Health News:ERT Achieves Cardiac Safety Milestone after Completing 150th TET Trial 2Health News:ERT Achieves Cardiac Safety Milestone after Completing 150th TET Trial 3Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 2Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 3Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 4Health News:My1Stop.com Named 2009 Inc. 500/5000 Honoree 2
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: